U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07549958) titled 'PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)' on April 17.
Brief Summary: This is a phase 1, open-label clinical trial determining the recommended Phase 2 dose of Gemcitabine with Nab-paclitazel with or without Pitavastatin in subjects with unresectable pancreatic adenocarcinoma (uPDAC). These are subjects who are already receiving Gemcitabine for treatment of their disease.
Study Start Date: March 24
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Pancreatic Cancer Metastatic
Intervention:
DRUG: Pitavastatin
Given PO
Recruitment Status: RECRUITING
Sponsor: Univers...